Form 4 for RANI Rani Therapeutics Holdings, Inc.
Accepted 2026-07-21 18:29:00 ET · period of report 2026-07-17 · accession 0001869579-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-21 18:29 | 2026-07-17 | RANI | Imran Talat | CEO, Dir | P - Purchase | $0.7198 | +35.0K | 469.7K | +8% | +$25.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-07-17 | P | A | 35,000 | $0.7198 | 469,736 | D | — | — | (F1) Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |